spevatamig

San Diego, California, August 14, 2026 Phanes Therapeutics, Inc., a clinical-stage biotechnology company focused on immuno-oncology drug discovery and...

SAN DIEGO, May 28, 2026 Phanes Therapeutics announced updated positive Phase 2 clinical trial results for spevatamig (PT886) in...

San Diego, California, USA – April 22, 2026 In a significant development in oncology drug innovation, Phanes Therapeutics has...

SAN DIEGO, April 7, 2026 Phanes Therapeutics, Inc. has announced the initiation of the dose expansion phase in its...